BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Venture capital

  Building Pharma’s Farm System: Eli Lilly, Boehringer Ingelheim, More Invest in the Future

  While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and venture funds to uncover cutting-edge scientific trends, determine their future focus points and even carve out a niche in an emerging geographical hotspot.

  August 6, 2025

   · 

  5 min read

   · 

  Heather McKenzie
• 

  China

  Big Pharma Provides Lifeline to Chinese Companies Struggling To Survive

  Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is only scratching at the surface of partnership-ready biotechs in the region.

  August 6, 2025

   · 

  7 min read

   · 

  Leslie Zhen Liang
• 

  Opinion

  How AI Can Help Pharma Companies Adapt to Policy Pressures

  The regulatory environment is placing extreme pricing pressure on pharmaceutical manufacturers. Their success in the market depends on mounting an agile response.

  August 6, 2025

   · 

  5 min read

   · 

  Jesse Mendelsohn
• 

  Layoffs

  BioNTech Cuts 90 Jobs Amid ‘Strategic Alignment’

  BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing operations in Gaithersburg, Maryland.

  August 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Biopharma CEOs Can’t Dodge Policy Questions as Trump Lobs Wrench into Earnings Season

  From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

  August 6, 2025

   · 

  6 min read

   · 

  Annalee Armstrong
• 

  Tariffs

  Trump Threatens Highest Pharma Tariffs So Far at 250%

  President Donald Trump plans to start with a “small tariff” on pharmaceutical imports before ramping duties up to 250% within a year and a half.

  August 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  ‘Execution, Execution, Execution’: Novo’s New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline

  Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of reallocating resources to the company’s “main core” of metabolic disease.

  August 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Terns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity Market

  Terns, once a rising star in obesity and the MASH space, will refocus on cancer and partner out a handful of obesity assets.

  August 6, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Earnings

  Bayer Expects More Layoffs To Come Following a Brutal Two Years of Cost-Cutting

  The German giant has already trimmed more than 10,000 employees since initiating a massive restructuring initiative in July 2023. Bayer said even more cuts are coming as it weathers up-and-down sales across its portfolio.

  August 6, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Brain cancer

  FDA Greenlights Jazz’s Dordaviprone, First New Treatment for Ultra-Rare Brain Tumor

  The small molecule drug, acquired by Jazz Pharmaceuticals in its $935 million Chimerix pick-up this spring, is intended for relapsed adult and pediatric patients with H3 K27M mutations.

  August 6, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky